Compare DVA & SF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DVA | SF |
|---|---|---|
| Founded | 1994 | 1890 |
| Country | United States | United States |
| Employees | N/A | 9000 |
| Industry | Misc Health and Biotechnology Services | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 11.4B |
| IPO Year | 2003 | N/A |
| Metric | DVA | SF |
|---|---|---|
| Price | $192.16 | $70.72 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $156.75 | $90.33 |
| AVG Volume (30 Days) | 697.3K | ★ 1.2M |
| Earning Date | 05-05-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 1.76% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.87 | N/A |
| Revenue | ★ $13,643,069,000.00 | N/A |
| Revenue This Year | $3.85 | $14.58 |
| Revenue Next Year | $3.07 | $8.03 |
| P/E Ratio | $66.95 | ★ $20.53 |
| Revenue Growth | ★ 6.46 | N/A |
| 52 Week Low | $101.00 | $67.96 |
| 52 Week High | $202.69 | $134.74 |
| Indicator | DVA | SF |
|---|---|---|
| Relative Strength Index (RSI) | 57.52 | 37.17 |
| Support Level | $191.57 | $69.31 |
| Resistance Level | $202.63 | $74.07 |
| Average True Range (ATR) | 5.15 | 1.60 |
| MACD | -2.15 | -0.01 |
| Stochastic Oscillator | 36.21 | 32.17 |
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
Stifel Financial is a diversified financial-services provider that generates revenue from wealth management, investment banking, and lending. The firm was founded in 1890 as a St. Louis-based full-service brokerage but has been transformed under CEO Ronald Kruszewski through a slew of acquisitions into a globally competitive wealth manager, investment bank, and retail and institutional brokerage. The firm generated $5.5 billion in revenue in 2025, with roughly two-thirds derived from wealth management and one-third derived from investment banking and trading.